VistaGen Therapeutics to Present at Two Investor Conferences in June
May 20, 2021 08:00 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to...
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
May 04, 2021 08:00 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
April 27, 2021 08:00 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
March 22, 2021 08:30 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
March 16, 2021 07:46 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
March 11, 2021 08:30 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation...
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
February 11, 2021 16:30 ET
|
VistaGen Therapeutics, Inc.
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder...
VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
January 06, 2021 08:00 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
December 30, 2020 09:00 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
December 22, 2020 16:01 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of...